These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
262 related articles for article (PubMed ID: 29359168)
1. SERINC as a Restriction Factor to Inhibit Viral Infectivity and the Interaction with HIV. Gonzalez-Enriquez GV; Escoto-Delgadillo M; Vazquez-Valls E; Torres-Mendoza BM J Immunol Res; 2017; 2017():1548905. PubMed ID: 29359168 [TBL] [Abstract][Full Text] [Related]
2. Effect of HIV-1 Env on SERINC5 Antagonism. Beitari S; Ding S; Pan Q; Finzi A; Liang C J Virol; 2017 Feb; 91(4):. PubMed ID: 27928004 [TBL] [Abstract][Full Text] [Related]
3. SERINC3 and SERINC5 restrict HIV-1 infectivity and are counteracted by Nef. Usami Y; Wu Y; Göttlinger HG Nature; 2015 Oct; 526(7572):218-23. PubMed ID: 26416733 [TBL] [Abstract][Full Text] [Related]
4. The Antagonism of HIV-1 Nef to SERINC5 Particle Infectivity Restriction Involves the Counteraction of Virion-Associated Pools of the Restriction Factor. Trautz B; Pierini V; Wombacher R; Stolp B; Chase AJ; Pizzato M; Fackler OT J Virol; 2016 Dec; 90(23):10915-10927. PubMed ID: 27681140 [TBL] [Abstract][Full Text] [Related]
5. Functional Interplay Between Murine Leukemia Virus Glycogag, Serinc5, and Surface Glycoprotein Governs Virus Entry, with Opposite Effects on Gammaretroviral and Ebolavirus Glycoproteins. Ahi YS; Zhang S; Thappeta Y; Denman A; Feizpour A; Gummuluru S; Reinhard B; Muriaux D; Fivash MJ; Rein A mBio; 2016 Nov; 7(6):. PubMed ID: 27879338 [TBL] [Abstract][Full Text] [Related]
6. Murine Leukemia Virus Glycosylated Gag Reduces Murine SERINC5 Protein Expression at Steady-State Levels via the Endosome/Lysosome Pathway to Counteract SERINC5 Antiretroviral Activity. Li S; Ahmad I; Shi J; Wang B; Yu C; Zhang L; Zheng YH J Virol; 2019 Jan; 93(2):. PubMed ID: 30355687 [TBL] [Abstract][Full Text] [Related]
7. S2 from equine infectious anemia virus is an infectivity factor which counteracts the retroviral inhibitors SERINC5 and SERINC3. Chande A; Cuccurullo EC; Rosa A; Ziglio S; Carpenter S; Pizzato M Proc Natl Acad Sci U S A; 2016 Nov; 113(46):13197-13202. PubMed ID: 27803322 [TBL] [Abstract][Full Text] [Related]
8. Differential Pressures of SERINC5 and IFITM3 on HIV-1 Envelope Glycoprotein over the Course of HIV-1 Infection. Beitari S; Pan Q; Finzi A; Liang C J Virol; 2020 Jul; 94(16):. PubMed ID: 32493821 [TBL] [Abstract][Full Text] [Related]
9. Potent Enhancement of HIV-1 Replication by Nef in the Absence of SERINC3 and SERINC5. Wu Y; Olety B; Weiss ER; Popova E; Yamanaka H; Göttlinger H mBio; 2019 Jun; 10(3):. PubMed ID: 31186327 [TBL] [Abstract][Full Text] [Related]
10. The host-cell restriction factor SERINC5 restricts HIV-1 infectivity without altering the lipid composition and organization of viral particles. Trautz B; Wiedemann H; Lüchtenborg C; Pierini V; Kranich J; Glass B; Kräusslich HG; Brocker T; Pizzato M; Ruggieri A; Brügger B; Fackler OT J Biol Chem; 2017 Aug; 292(33):13702-13713. PubMed ID: 28659343 [TBL] [Abstract][Full Text] [Related]
11. Relative resistance of patient-derived envelope sequences to SERINC5-mediated restriction of HIV-1 infectivity. Nkuwi E; Judicate GP; Tan TS; Barabona G; Toyoda M; Sunguya B; Kamori D; Ueno T J Virol; 2023 Oct; 97(10):e0082323. PubMed ID: 37768085 [TBL] [Abstract][Full Text] [Related]
13. TIM-mediated inhibition of HIV-1 release is antagonized by Nef but potentiated by SERINC proteins. Li M; Waheed AA; Yu J; Zeng C; Chen HY; Zheng YM; Feizpour A; Reinhard BM; Gummuluru S; Lin S; Freed EO; Liu SL Proc Natl Acad Sci U S A; 2019 Mar; 116(12):5705-5714. PubMed ID: 30842281 [TBL] [Abstract][Full Text] [Related]
14. Flow Cytometry Analysis of HIV-1 Env Conformations at the Surface of Infected Cells and Virions: Role of Nef, CD4, and SERINC5. Staropoli I; Dufloo J; Ducher A; Commere PH; Sartori-Rupp A; Novault S; Bruel T; Lorin V; Mouquet H; Schwartz O; Casartelli N J Virol; 2020 Feb; 94(6):. PubMed ID: 31852789 [TBL] [Abstract][Full Text] [Related]
15. A Conserved Acidic-Cluster Motif in SERINC5 Confers Partial Resistance to Antagonism by HIV-1 Nef. Stoneham CA; Ramirez PW; Singh R; Suarez M; Debray A; Lim C; Jia X; Xiong Y; Guatelli J J Virol; 2020 Mar; 94(7):. PubMed ID: 31941773 [TBL] [Abstract][Full Text] [Related]
16. An N-Glycosylated Form of SERINC5 Is Specifically Incorporated into HIV-1 Virions. Sharma S; Lewinski MK; Guatelli J J Virol; 2018 Nov; 92(22):. PubMed ID: 30158294 [TBL] [Abstract][Full Text] [Related]
17. The retroviral accessory proteins S2, Nef, and glycoMA use similar mechanisms for antagonizing the host restriction factor SERINC5. Ahmad I; Li S; Li R; Chai Q; Zhang L; Wang B; Yu C; Zheng YH J Biol Chem; 2019 Apr; 294(17):7013-7024. PubMed ID: 30862674 [TBL] [Abstract][Full Text] [Related]